Table 3. Pooled prevalence of Dengue virus infection in Nigeria.
| DENV biomarkers | Number of studies | Number of participants | Number of Dengue cases | Prevalence (%, 95% CI) | H | I2 | P-value |
|---|---|---|---|---|---|---|---|
| IgM seroprevalence | 14 | 4,965 | 834 | 16.8 (15.8 - 17.9) | 551 | 92.9 | <0.0001 |
| IgG seroprevalence | 10 | 4,107 | 1,424 | 34.7 (33.2 - 36.2) | 389 | 92.5 | <0.0001 |
| IgM/IgG seroprevalence | 4 | 1,458 | 89 | 6.1 (4.9 - 7.5) | 298 | 96.4 | <0.0001 |
| NS1 prevalence | 6 | 1,161 | 90 | 7.7 (6.3 - 9.4) | 3.09 | 19.3 | 0.19 |
| IgM/NS1 seroprevalence | 2 | 620 | 16 | 7.8 (4.6 - 12.4) | 1.53 | 20.1 | 0.13 |
| IgG/NS1 seroprevalence | 1 | 171 | 12 | 7.0 (3.7 - 11.9) | NA | NA | NA |
| Viral RNA prevalence | 3 | 323 | 25 | 7.7 (5.1 - 11.2) | 3.16 | 16.1 | 0.06 |
| Neutralizing antibody prevalence | 1 | 1,948 | 13 | 0.7 (0.36 - 1.1) | NA | NA | NA |
DENV, Dengue virus; CI, confidence interval; H, heterogeity index; IgM, immunoglobulin M; IgG, immunoglobulin G; NSI, non-structural protein-1; RNA, ribonucleic acid; NA, not available.